Today: 9 June 2026
Boeing stock gets a new $277 target — but a 737 MAX supply signal keeps nagging
7 January 2026
2 mins read

Boeing stock gets a new $277 target — but a 737 MAX supply signal keeps nagging

NEW YORK, Jan 7, 2026, 09:37 (EST)

  • Bernstein raised its Boeing price target to $277 from $267 and kept an Outperform rating.
  • A BNP Paribas report flagged December 737 MAX fuselage shipments in the low 30s, below Boeing’s 42-a-month target.
  • Boeing renewed a three-year, platinum-level sponsorship deal for EAA AirVenture Oshkosh.

Boeing Co shares ticked higher on Tuesday after Bernstein lifted its price target to $277, the latest sign that some on Wall Street think the planemaker’s turnaround has more room to run. The note landed as traders kept one eye on 737 MAX supply data that suggests the ramp remains touchy.

The call matters now because Boeing’s recovery still depends on simple things: build more jets, deliver them on time, collect the cash. Investors have been quick to react to any hint that parts flow is slipping again, especially on the narrow-body line that drives most commercial output.

Deliveries are the real choke point. That’s when a plane is handed to an airline and a big chunk of the money typically comes in, so a supplier slowdown can show up fast in cash expectations even if demand holds.

Bernstein analyst Douglas S. Harned raised the target from $267 to $277 while keeping a Buy-equivalent rating, MarketScreener reported. A “price target” is an analyst’s estimate of where a stock should trade over the next year, not a promise. https://www.marketscreener.com/news/boeing…

A BNP Paribas Equity Research report estimated that 737 MAX fuselage shipments — the fuselage is the main body of the aircraft — moved from Spirit AeroSystems’ Wichita plant fell to the low 30s in December, below Boeing’s monthly target of 42, Flying magazine reported. The same report suggested 787 Dreamliner output ran at about six a month, close to Boeing’s target of seven, and analysts pointed to holiday seasonality as one possible reason for the December dip.

TipRanks said Bernstein SocGen also tagged Boeing as its “top pick” in the U.S. for 2026, citing progress on the 737 and 787 programs over the past six months. The site said the new target implied roughly 21% upside versus Tuesday’s levels. https://www.tipranks.com/news/top-pick-in-…

Boeing has also tried to keep its brand in front of aviation customers and enthusiasts. It renewed its platinum-level sponsorship of the Experimental Aircraft Association’s AirVenture Oshkosh fly-in under a new three-year deal; “It’s an ideal stage to showcase Boeing’s diverse products and services,” Boeing Global Services chief executive Chris Raymond said, while EAA CEO Jack Pelton said the youth-admission support had brought nearly 500,000 kids to the show over the past three years. https://www.eaa.org/airventure/eaa-airvent…

Boeing’s main rival Airbus is due to publish audited full-year delivery data on Jan. 12 after trimming its 2025 goal because of supplier snags. Investors have been using delivery pace as a blunt scoreboard across the industry as airlines press manufacturers for jets.

But the story can still turn the other way. If supplier flows stay soft or regulators force fresh pauses after any quality slip, deliveries move right, cash moves right, and the stock’s “target” math starts to look optimistic.

Stock Market Today

  • Soybean Prices Decline Amid Lower Export Shipments and Reduced Speculative Positions
    June 9, 2026, 9:21 AM EDT. Soybean prices fell between 2 and 5 ½ cents on Monday, with the national average cash price dropping to $10.58 3/4 per bushel. Export shipments for the week ending June 4 decreased by 21.2% from the previous week, totaling 398,186 MT, and are down 28.8% year-over-year. Key buyers included Egypt, China, and Mexico. Marketing year exports stand 20.3% lower compared to last year. Meanwhile, speculative traders reduced their net long positions in soybean futures and options by 33,502 contracts, signaling cautious market sentiment. Soymeal and soy oil futures also declined modestly. A private export sale of 264,000 MT was reported for the 2026/27 season, but overall market pressure weighs on prices going into the week.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Intel stock today: INTC steadies before the bell as CES “Panther Lake” chips put 18A under the microscope
Previous Story

Intel stock today: INTC steadies before the bell as CES “Panther Lake” chips put 18A under the microscope

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings
Next Story

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

Go toTop